German startup Biotx AI leverages a vast curated genome-wide association study (GWAS) dataset with phenotypic and drug molecule data to predict disease causality and identify optimal drug targets. Their informatics platform employs Mendelian randomization and machine learning to refine candidate selection and reposition existing drugs. Collaborations and recent publications highlight the platform's capability to accelerate drug discovery and optimize clinical development paths.